Amarantus Completes Sublicense of ESS, MANF and Phenoguard to Emerald Organic Products
January 02, 2020 at 08:14 am EST
Amarantus Bioscience Holdings, Inc. announced that it has completed an exclusive worldwide sublicense agreement for development rights of Cutanogen Corporation’s and MANF Therapeutics, Inc.’s pipelines to Emerald Organic Products, a diversified cannabidiol -focused health sciences company. Emerald now has development rights to Engineered Skin Substitute, mesencephalic astrocyte-derived neurotrophic factor and PhenoGuard for all applications. RHK Capital, a boutique Connecticut-based investment bank, advised Emerald on the transaction.